Quick-Med seeks SEC permission to suspend reporting

Upon filing of the Form 15, the Company will no longer be obligated to file certain Exchange Act reports with the SEC, including annual reports under Form 10-K, quarterly reports under Form 10-Q and current reports under Form 8-K unless the SEC denies the effectiveness of Form 15, in which case the Company is required to file all the reports within 60 days of such denial.

The Company's board of directors determined, after careful consideration, that suspending reporting is in the overall best interests of the Company. Among other factors, the board of directors considered the cost savings to be realized by the Company by eliminating its obligations to file reports with the SEC.

One of the reasons that the Company is eligible to suspend its reporting obligations is because it has fewer than 300 record holders of its common stock as of the date hereof and it anticipates maintaining such eligibility until the filing of the Form 15.

The Company expects that as a result of the filing of the Form 15 its common stock will be removed from trading on the OTCQB Marketplace. Shares may begin trading on the OTCPink Marketplace, but there can be no assurance that there will be a market for the Company's securities, and the liquidity of such trading market may be very limited.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing and commercializing proprietary, broad-based technologies for the consumer and healthcare markets. The Company's NIMBUS technology is the first FDA-cleared, non-leaching antimicrobial technology available in a wound dressing.

Its Stay Fresh technology provides highly durable antimicrobial protection for apparel and other textile applications, with consumer applications of Stay Fresh Technology having EPA registration for the treated articles, as well as an FDA clearance for an antibacterial medical textile product.

Quick-Med Technologies